Breakthrough biotechs with a bright future
Fidelity’s Chris Lin considers two biotech companies well-positioned to revolutionize drug development and the treatment of major diseases.
- Fidelity Portfolio Manager Chris Lin thinks biotechnology firms Alnylam Pharmaceuticals and Regeneron Pharmaceuticals have some of the most effective prescriptions for tackling and potentially treating major diseases with their cutting-edge advancements in RNA interference and monoclonal antibody therapy, respectively.
- "These two industry-leading biotech companies are at the forefront of these innovative therapies and are advancing health care, raising the prospects for durable earnings growth," says Lin, who has chosen both stocks for Fidelity Advisor® OTC Fund [Fidelity® OTC Portfolio].
- In managing the fund since 2017, Lin invests primarily in dynamic growth companies listed on the Nasdaq Stock Market. In particular, he focuses on companies he believes have above-average earnings-growth potential with a sustainable business model, for which the market has mispriced the rate and/or durability of growth.
- The health care sector represented 7% of the tech-focused portfolio as of January 31, led by Alnylam and Regeneron. The former specializes in RNA interference, or RNAi, a promising category of therapeutics, according to Lin.
- "RNAi is designed to inhibit disease-causing proteins at their source, offering a novel approach to treatment," Lin explains. "Unlike traditional therapies that intervene later in the disease pathway, RNAi targets messenger RNA, which is upstream of disease-causing proteins and sometimes referred to as 'gene silencing technology,' potentially providing a more effective solution for patients."
- Alnylam's durable competitive advantage, according to Lin, lies in its industry-leading understanding of RNA biology, extensive experience with finding good druggable RNA targets, skill at solving the longstanding problem of delivering RNAi therapies to the right organs, and track record of maintaining excellent safety profiles for its therapies.
- With two successful drugs, Onpattro® and Amvuttra®, already making a significant impact in treating polyneuropathy and cardiovascular conditions associated with transthyretin protein amyloidosis using this platform, Lin believes that Alnylam is poised for continued growth.
- Meanwhile, Regeneron is the market leader for antibodies in oncology, as well as inflammatory and eye diseases. Lin likes the company's robust pipeline, market-leading treatments and commitment to improving patient outcomes.
- The company also is on the cusp of receiving approval for a breakthrough novel treatment for multiple myeloma, which Lin considers a meaningful milestone that could improve treatment for this blood cancer.
- Additionally, he notes that Regeneron's Eylea® has already set a high bar in treating retinal diseases, offering patients hope and improved vision, while Dupixent® has become a household name for managing a variety of inflammatory conditions, including atopic dermatitis and asthma.
- "Alnylam and Regeneron exemplify not only above-average, durable earnings growth, but also a strong commitment to improving lives and advancing medical science," concludes Lin.
Fidelity Advisor OTC Fund (FOTHX)
Seeks capital appreciation.
Related insights
View all


For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.